{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-86","upperLimit":"355","value":"-15.7"},{"groupId":"OG001","lowerLimit":"-94","upperLimit":"156","value":"10.6"}]}],"title":"Week 44"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-78","upperLimit":"355","value":"-17.2"},{"groupId":"OG001","lowerLimit":"-94","upperLimit":"125","value":"9.3"}]}],"title":"Week 92"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"The percent change in B-NAG was calculated as \\[Week 44 or 92 B-NAG minus Baseline B-NAG\\] divided by Baseline B-NAG, multiplied by 100. For the Week 44 analysis, the last available value on/before Week 44 was used in the calculation. For the Week 92 analysis, the last available value on/before Week 92 was used in the calculation.","dispersionType":"Full Range","groups":[{"description":"Participants with multiple myeloma received ibandronate via 15-minute IV infusion as 6 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG000","title":"Ibandronate"},{"description":"Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG001","title":"Zoledronate"}],"paramType":"MEDIAN","populationDescription":"ITT Population. The \"Number of Participants Analyzed\" reflects the total number of participants who provided evaluable data for the endpoint.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 44, 92","title":"Percent Change From Baseline in N-Acetyl-Beta-D-Glucosaminidase (B-NAG)","type":"SECONDARY","unitOfMeasure":"percent change"}